Skip to content
BiologicalX

Comparison

Berberine vs Sermorelin

Side-by-side of Berberine and Sermorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Berberine

  • Lowers HbA1c by ~0.7% versus placebo at 1500 mg/day across 27-trial meta-analysis (Lan 2015)
  • Roughly comparable to metformin on fasting glucose and HbA1c in small head-to-head RCTs (Yin 2008)
  • Reduces LDL cholesterol 10-20% and triglycerides 15-25% via PCSK9 inhibition
  • Activates AMPK, the cellular energy sensor that drives insulin-independent glucose uptake
  • Oral bioavailability under 1%; dihydroberberine is the higher-absorption alternative at lower doses
  • GI side effects affect 10-30% at 1500 mg/day; split dosing with meals reduces incidence

Sermorelin

  • Synthetic 29-amino-acid GHRH fragment; FDA approved 1997 for pediatric GH deficiency as Geref
  • Voluntarily discontinued by Serono in 2008 for commercial reasons; not safety-related
  • Compounded by 503A/503B pharmacies for off-label adult anti-aging and body-composition use
  • Produces physiologic pulsatile GH release; ~10 to 20 minute plasma half-life
  • Standard anti-aging clinic protocol: 200 to 500 mcg subcutaneously pre-bed, often with ipamorelin
  • Banned by WADA under S2 (peptide hormones, growth factors)

Side-by-side

Attribute Berberine Sermorelin
Category natural peptide
Also known as berberine HCl, berberine hydrochloride Sermorelin acetate, GRF 1-29, Geref, GHRH (1-29) NH2
Half-life (hr) 3 0.25
Typical dose (mg) 1500 0.3
Dosing frequency 3x daily with meals 1-2x daily
Routes oral subcutaneous
Onset (hr) 2 0.25
Peak (hr) 3 0.5
Molecular weight 336.36 3357.88
Molecular formula C20H18NO4+ C149H246N44O42S
Mechanism Activates AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and lipogenesis while increasing peripheral glucose uptake. Inhibits PCSK9 transcription, modulates bile acid signaling, and shifts gut microbiome composition. Synthetic 29-amino-acid GHRH fragment that binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH synthesis and release while preserving the GH-IGF-1 negative feedback loop.
Legal status Dietary supplement (US, EU, UK, Canada); Rx in some Asian jurisdictions FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA
WADA status allowed banned
DEA / Rx Not scheduled Rx only via compounding (no controlled-substance schedule)
Pregnancy Contraindicated (kernicterus risk in neonates) Category C (historical labeling); not recommended in pregnancy
CAS 2086-83-1 86168-78-7
PubChem CID 2353 16129617
Wikidata Q411435 Q416620

Safety profile

Berberine

Common side effects

  • constipation
  • diarrhea
  • abdominal cramping
  • flatulence
  • nausea

Contraindications

  • pregnancy
  • lactation
  • neonatal jaundice
  • severe liver disease

Interactions

  • metformin: additive HbA1c reduction; additive GI side effects(moderate)
  • insulin or sulfonylureas: additive hypoglycemia risk; dose adjustment may be required(major)
  • statins (simvastatin, atorvastatin): CYP3A4 inhibition raises statin plasma levels(moderate)
  • cyclosporine: raises cyclosporine levels through CYP3A4 and P-gp inhibition(major)
  • calcium channel blockers (amlodipine): elevated plasma levels via CYP3A4 inhibition(moderate)

Sermorelin

Common side effects

  • injection-site pain or irritation
  • transient flushing
  • headache
  • vivid dreams (pre-bed dosing)

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • diabetic retinopathy (theoretical)
  • untreated hypothyroidism

Interactions

  • ipamorelin: synergistic GH release via parallel GHRH and ghrelin pathways; standard anti-aging clinic pairing(minor)
  • CJC-1295: pharmacologically redundant (both GHRH-pathway); typically not stacked(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: blunt GH response; reduce expected efficacy(moderate)
  • levothyroxine (untreated hypothyroidism): untreated hypothyroidism blunts GH response; correct thyroid first(moderate)

Which Should You Take?

Berberine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Sermorelin is the right call when one of the conditionals below applies.

  • If your priority is metabolic health and glucose control, pick Berberine.
  • If your priority is cardiovascular health, pick Berberine.
  • If your priority is growth-hormone axis, pick Sermorelin.
  • If your priority is post-training recovery, pick Sermorelin.

Edge case: If you want to avoid FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA, Berberine is the more accessible choice.

Default choice: Berberine. Lower friction to source, and broader goal coverage. Reach for Sermorelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Berberine and Sermorelin?

Berberine and Sermorelin differ in category (natural vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Berberine or Sermorelin?

Berberine half-life is 3 hours; Sermorelin half-life is 0.25 hours.

Can you stack Berberine with Sermorelin?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper